Armistice Capital’s Immunovant IMVT Stock Holding History

Armistice Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$88.6M	Sell	3,564,916 -2,182,239	-38%	-$56.5M	1.57%	11
2025 Q4	$146M	Sell	5,747,155 -88,845	-2%	-$1.98M	1.74%	5
2025 Q3	$94.1M	Buy	5,836,000 +636,000	+12%	+$10.3M	1.4%	8
2025 Q2	$83.2M	Buy	5,200,000 +700,000	+16%	+$10.6M	1.44%	8
2025 Q1	$76.9M	Buy	4,500,000 +629,414	+16%	+$13.2M	1.15%	10
2024 Q4	$95.9M	Buy	3,870,586 +322,586	+9%	+$9.15M	1.31%	8
2024 Q3	$101M	Buy	3,548,000 +151,091	+4%	+$4.46M	1.62%	8
2024 Q2	$89.7M	Buy	3,396,909 +1,232,909	+57%	+$35.1M	1.13%	8
2024 Q1	$69.9M	Buy	2,164,000 +728,000	+51%	+$26.6M	0.93%	11
2023 Q4	$60.5M	Buy	1,436,000 +400,123	+39%	+$14.7M	0.83%	23
2023 Q3	$39.8M	Buy	+1,035,877	New	+$23.4M	0.61%	33

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Armistice Capital's IMVT Position: Q1 2026 in Review

Armistice Capital reduced its Immunovant (IMVT) stake by 38% in Q1 2026, selling an estimated $56.5M and leaving 3,564,916 shares worth $88.6M. The position accounts for 1.57% of the portfolio, ranked #11.

Armistice Capital first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $146M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Armistice Capital held 3,564,916 shares of Immunovant worth $88.6M as of Q1 2026.
Armistice Capital sold 2,182,239 Immunovant shares in Q1 2026, an estimated $56.5M.
Immunovant made up 1.57% of Armistice Capital's portfolio in Q1 2026, its #11 holding.
Armistice Capital first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
Armistice Capital's Immunovant position peaked at $146M in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.